Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niacin + omega-3 acid ethyl esters
- Development stage
- Unknown
- Lead developer
- University of South Dakota
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of extended-release niacin (Niaspan) and omega-3 acid ethyl esters (Lovaza/Omacor). It was evaluated in a Phase 4 clinical trial (NCT00286234) conducted by the University of South Dakota for the treatment of metabolic syndrome and hypertriglyceridemia. Niacin (nicotinic acid) primarily acts as an agonist of the hydroxycarboxylic acid receptor 1 (HCAR1) and inhibits hepatic diacylglycerol acyltransferase-2 (DGAT2), leading to reduced triglyceride synthesis and increased HDL cholesterol levels. Omega-3 fatty acids (EPA and DHA) primarily lower triglyceride levels by activating peroxisome proliferator-activated receptor alpha (PPAR-alpha) and inhibiting acyl-CoA:1,2-diacylglycerol acyltransferase, which promotes fatty acid oxidation and reduces hepatic VLDL production. The combination aims to provide synergistic lipid-lowering effects and improve insulin sensitivity in patients with metabolic syndrome without adversely affecting glucose levels.
- Brand names
- NiaspanLovazaOmacor
- Other names
- combined treatment-University of South Dakota-metabolic syndrome-hypertriglyceridemianiacin + omega-3 acid ethyl estersNiaspan + LovazaNiaspan + Omacorextended-release niacin + omega-3 acid ethyl esters
02
Targets
HCAR1 (Hydroxycarboxylic acid receptor 1)PPARA (Peroxisome proliferator-activated receptor alpha)DGAT2 (Hepatic diacylglycerol acyltransferase 2)HCAR3 (Hydroxycarboxylic acid receptor 3)
Beyond the preview
Go deeper on niacin + omega-3 acid ethyl esters.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niacin + omega-3 acid ethyl esters.